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See Article, pages 139–147A very interesting and concise study by Clarke et al. in this
month’s issue of the Journal highlights important principles about
the genetic determinants of drug disposition and toxicity, and the
impact of underlying liver disease on adverse events from medi-
cations. The ﬁndings provide an opportunity to consider the cur-
rent state of our knowledge about how genetic variations affect
drug metabolism (i.e., pharmacogenomics), and to highlight
efforts being developed to integrate genetic information into
the clinical care of patients.
The Clarke study is the most recent work in a series of publi-
cations by the authors examining the behavior of the hepatic
uptake transporter organic ion transporting polypeptide-1B1
(OATP1B1) in drug disposition. This well-characterized mem-
brane transporter regulates the uptake of organic compounds
from the circulation into the hepatocyte where they can be
metabolized. OATP1B1 has a large number of genetic variants,
or single nucleotide polymorphisms (SNPs), that confer widely
variable uptake activity by the transporter [1]; variants that con-
fer reduced uptake lead to slower clearance of substrates, and
therefore higher blood levels. That is exactly the case with several
single nucleotide polymorphisms (SNPs) that have been linked to
increased risk of myopathy associated with statin drugs used to
treat hypercholesterolemia [1–3]. While statins are remarkably
safe in general, individuals with these variants can be at up to
20 times greater risk of myopathy. Moreover, because these
transporters have hundreds of substrates, altered activity can also
lead to many adverse drug-drug interactions, in addition to alter-
ing the pharmacokinetics of individual drugs [1].
As hepatologists know well, many patients with hypercholes-
terolemia who are treated with statins are also obese and have
metabolic syndrome complicated by non-alcoholic fatty liver dis-
ease (NAFLD) or non-alcoholic steatohepatitis (NASH). These con-
ditions introduce the confounding effect of underlying fatty liver
disease, which may further alter hepatic drug metabolism [4–6].
Additionally, the increased adiposemass in these patients can lead
to accumulation of lipophilic drugs in fat cells and hepatocytes.
The Clarke study examines how these two important vari-
ables, namely the genetic regulation of OATP1B1 activity andJournal of Hepatology 20
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Open access under CC BY-NC-ND license.the presence of concurrent fatty liver disease, inﬂuence the dis-
position of pravastatin in a mouse model. To do so, they used a
mouse in which the murine ortholog of OATP1B1 was genetically
knocked out, which was combined with a fatty liver model
induced by methionine choline deﬁcient (MCD) diet. While most
investigators in the ﬁeld recognize that the MCD diet is not a par-
ticularly faithful model of NASH (in part because there is no insu-
lin resistance), the authors have recently validated the relevance
of this model to human disease in a paper in press, by reporting
that both NASH in humans and the MCD diet in mice affect trans-
porter activity similarly. As expected, genetic loss of the trans-
porter alone led to increased circulating levels of pravastatin,
whereas MCD-induced fatty liver alone did not affect the disposi-
tion of the drug. However, when genetic depletion was combined
with MCD diet there was an almost threefold increase in plasma
area under the curve for the drug (AUC), and a 5–10 fold increase
in muscle levels of pravastatin.
While these ﬁndings raise concern and are certainly relevant
to patient management, the overall health beneﬁts of statins
are undeniable, and extensive clinical experience with statins
has shown the drugs to be remarkably safe. This is true even in
patients with metabolic syndrome, who are at heightened risk
of cardiovascular events and will beneﬁt from statins. Moreover,
statins do not confer an increased risk of hepatotoxicity in fatty
liver disease even when transaminases are elevated, which can
occur in up to 5% of patients overall [7]. Expert panels have
acknowledged that elevations in aminotransferases are a class
effect of statins, and the drugs can increase the incidence of liver
failure, transplant or death, but these latter catastrophic events
are extremely rare and probably idiosyncratic [8,9]. Common
sense would dictate, however, that while the risk of statin hepa-
totoxicity is no greater in patients with signiﬁcant liver disease, if
severe idiosyncratic injury occurs in these individuals, their out-
comes are likely to be worse than if their livers are normal.
The Clarke study raises the larger issue of the extraordinary
genetic variability in drug metabolism in all individuals, both
healthy patients and those with underlying liver disease. For
most drugs we still typically employ a ‘‘one dose ﬁts all’’ sche-
dule, yet this approach is increasingly naïve as evidence mounts
that genetics profoundly impact drug metabolism. To address
this issue, the NIDDK-sponsored Drug Induced Liver Injury
Network (DILIN) has been created in part to uncover genetic
determinants that might predispose patients to risk of hepatotox-
icity. Elucidating genetically determined idiosyncratic drug
toxicity is like ﬁnding a needle in a haystack, but it is a tractable14 vol. 61 j 1–2
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problem. It is also possible that rare cases of drug-induced liver
injury represents a conﬂuence of risks, including not only genetic
variability in metabolism or clearance, but also concurrent drug
use, as well as the impact of underlying disease in the liver or
other organs.
As the hundreds of genetic variants that inﬂuence drug metab-
olism and toxicity are catalogued, we expect this information to
somehow translate into improved management of patients.
Indeed, this is the promise of ‘‘personalized medicine’’. But how
do we translate complex genetic information into real world sys-
tems that are accessible to practitioners? The scale of the infra-
structure for such efforts is daunting, yet it is materializing. One
effort in the commercial sector is a DNA chip to genotype the
many variants of two major isoforms of cytochrome P450 that
together metabolize up to 25% of all prescription drugs (http://
molecular.roche.com/assays/Pages/AmpliChipCYP450Test.aspx).
With the increasing access to affordable whole human genome
sequencing, however, much more comprehensive genetic infor-
mation can now be integrated into these efforts. For example,
the National Human Genome Research Institute sponsors the
Electronic Medical Records and Genomics (eMERGE) Network,
which is a consortium of US medical research institutions
intended to ‘‘develop, disseminate and apply approaches to
research that combine DNA bio-repositories with electronic
medical record systems for large-scale, high-throughput genetic
research’’ [10]. Even this effort alone does not solve the problem,
as software needs to be developed that not only interprets genetic
information, but also translates it into clinical decision support
embedded in the electronic medical record, where it can direct
practitioners in real time to prescribe those drugs that are safe
in their patients, and to specify the correct dose [11].
While improving patient safety and outcomes by incorporat-
ing genomic information and clinical decision support tools is
not imminent, it is clear that the groundwork is being laid for
exactly such a cultural shift. Linking the levels of reimbursement
to patient outcomes by payors and government health care sys-
tems is likely to accelerate this shift. The concentric circles of
challenges and opportunities raised by the study of Clarke et al.
will steadily and incrementally transport us into a new era of
data-driven, individualized medication prescribing.2 Journal of Hepatology 2Conﬂict of interest
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